GLP-1 market size was evaluated at USD 24.97 billion in 2025 and is projected to reach around USD 77.36 billion by 2035, growing at a CAGR of 11.97% from 2026 to 2035
Nearly 75 percent of participants lost at least five percent of their body weight and 62 percent experienced the symptoms noted above
Available safety data for IGF-1 DES remain limited, with most information derived from mechanistic research, preclinical studies, and practitioner-reported experience
PlexusDx's commitment means "your dose may need to go up, your price won't." This transparency removes the financial penalty typically associated with dose adjustments in traditional pharmacy settings
Dosing strategy : Most patients benefit from divided doses rather than a single large dose
The younger generation is using these drugs slightly differently, Tebra's survey suggests